Microbot Medical Inc. (NASDAQ: MBOT), a US-based medical device company that develops, manufactures and distributes the Liberty Endovascular Robotic System, announced on Wednesday that the Japanese Patent Office has granted its first patent in Japan, covering the core Liberty technology.
The patent protects a compact robotic device designed for use in the remote delivery and manipulation of guidewires and catheters. Over the past 90 days, Microbot Medical has also secured patents in the United States, China and Israel.
On September 8, 2025, the company received marketing clearance for the Liberty System from the US Food and Drug Administration. It has since accelerated commercial launch plans, targeting an estimated 2.5 million peripheral endovascular procedures performed annually in the United States.
Microbot Medical said its global intellectual property strategy is designed to protect and monetise its technology as it evaluates expansion into markets that traditionally accept FDA-cleared devices, however, its initial focus is on the US market.
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
Celltrion launches AVTOZMA IV in the United States following FDA approval
Vanda Pharmaceuticals agrees collaborative framework to resolve US FDA disputes
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Pharming receives FDA priority review for leniolisib in children with APDS
Renalytix submits CE Mark application for kidneyIntelX.dkd in Europe
Vicore Pharma's buloxibutid receives orphan drug designation in Japan
Novartis to launch US direct-to-patient platform for Cosentyx